Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026)
Argenx Se's (ARGX) quarterly Income from Continuing Operations came in at $601.0 million in Q2 2026, up 82.99% on a YoY basis from $328.4 million in Q2 2025, and up 20.44% quarter-over-quarter from $499.0 million in Q1 2026.
Analysis
Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Income from Continuing Operations for 11 consecutive years, with $601.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations rose 82.99% year-over-year to $601.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.8 billion (up 3935.77% YoY), and the FY2025 full-year result was $1.3 billion, up 290.92% from the prior year.
- Income from Continuing Operations climbed to $601.0 million in Q2 2026 per ARGX's latest filing, from $499.0 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $601.0 million in Q2 2026 and bottomed at -$603.8 million in Q4 2024.
- Historically, Income from Continuing Operations has averaged $35.4 million across 5 years, with a median of -$51.5 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 2504.39% in 2024, then surged 656.0% in 2025.
- Over 5 years, Income from Continuing Operations stood at -$43.9 million in 2022, then surged by 47.14% to -$23.2 million in 2023, then tumbled by 2504.39% to -$603.8 million in 2024, then surged by 145.32% to $273.6 million in 2025, then soared by 119.63% to $601.0 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered $601.0 million, $499.0 million, and $273.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -1.04 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 601.00 Mn |
| Mar 31, 2026 | 499.00 Mn |
| Dec 31, 2025 | 273.64 Mn |
| Sep 30, 2025 | 427.85 Mn |
| Jun 30, 2025 | 328.44 Mn |
| Mar 31, 2025 | 235.36 Mn |
| Dec 31, 2024 | -603.80 Mn |
| Sep 30, 2024 | 84.64 Mn |
| Jun 30, 2024 | -59.07 Mn |
| Mar 31, 2024 | -87.10 Mn |
| Dec 31, 2023 | -23.18 Mn |
| Sep 30, 2023 | -93.92 Mn |
| Jun 30, 2023 | -73.35 Mn |
| Mar 31, 2023 | -123.49 Mn |
| Dec 31, 2022 | -43.86 Mn |
| Sep 30, 2022 | -247.01 Mn |
| Jun 30, 2022 | -225.21 Mn |
| Mar 31, 2022 | -232.96 Mn |
| Dec 31, 2021 | -251.94 Mn |
| Sep 30, 2021 | -228.12 Mn |